Metraipolis › archive › dc_8dc742e9725d
MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing — Europe PMC PMID:42159893
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42159893
- DOI
- 10.1007/s11060-[numero omesso]-0
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T13:42:53.007Z
- SHA-256 of the archived text
f067a74af6927926eac0f3d10802788cae282c09980bba79f964365e9df9d82a- Stable URL of this page
https://metraipolis.com/documento/dc_8dc742e9725d
How to cite
MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing — Europe PMC PMID:42159893 — Europe PMC (en), https://europepmc.org/article/MED/42159893 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8dc742e9725d (Metraipolis archive dc_8dc742e9725d, sha256 f067a74af6927926eac0f3d10802788cae282c09980bba79f964365e9df9d82a)
BibTeX
@misc{dc8dc742e9725d,
title = {MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing — Europe PMC PMID:42159893},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42159893},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8dc742e9725d; sha256 f067a74af6927926eac0f3d10802788cae282c09980bba79f964365e9df9d82a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42159893. Agents can read the archived copy with the MCP tool read_document.